A Portfolio of Promise

Throughout our heritage, we have continued our commitment to innovation, with a focus for the past 7 years on developing our own product candidates in neurology and psychiatry.

The Supernus Pharmaceuticals Pipeline of Novel CNS Products

Product Indication Status
SPN-810 Impulsive Aggression in ADHD Completed Phase IIb
SPN-812 ADHD Completed Phase IIa
SPN-809 Depression IND filed

NDA=New Drug Application; IND=Investigational New Drug (application). ADHD=attention-deficit hyperactivity disorder;

Advancing Treatments in Neurology

Learn more about our late-stage neurology portfolio.

Learn More

Advancing Treatments in Psychiatry

Learn more about our psychiatry portfolio.

Learn More